Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422162 | 1.00 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1MAPK10MEN1 | |
| SCHEMBL3420625 | 0.90 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3420630 | 0.90 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3421574 | 0.90 | LMNA (0.43) | RAB9ASMN1; SMN2NPC1KDM4EHPGD | |
| SCHEMBL3421573 | 0.90 | LMNA (0.43) | RAB9ASMN1; SMN2NPC1KDM4EHPGD | |
| SCHEMBL2887690 | 0.89 | ALDH1A1 (0.47) | RAB9ASMN1; SMN2NPC1MAPK10MEN1 | |
| SCHEMBL2887687 | 0.89 | ALDH1A1 (0.47) | RAB9ASMN1; SMN2NPC1MAPK10MEN1 | |
| SCHEMBL3415355 | 0.89 | L3MBTL1 (0.43) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3415358 | 0.89 | L3MBTL1 (0.43) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL2893552 | 0.88 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2009-09-10 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1896484-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1851229-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006125813-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006084869-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | MKI67, CCNT1, RB1 | RAB9A 1361/4885SMN1; SMN2 2960/4885NPC1 4077/4885 |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNO, CCNY, CCNT1 | RAB9A 908/4885SMN1; SMN2 4393/4885NPC1 3465/4885 |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | RAB9A 1252/4885SMN1; SMN2 4289/4885NPC1 2778/4885 |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | RAB9A 1221/4885SMN1; SMN2 3422/4885NPC1 4618/4885 |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | RAB9A 1361/4885SMN1; SMN2 3283/4885NPC1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.